As Bharat Biotech's bid for approval of Covaxin in the US gets rejected, we ask about the many questions surrounding Covaxin. Why is the phase 3 trial data not out yet, and is there a lack of transparency over Covaxin. Tamanna Inamdar, Senior Editor, ET Now speaks to Dr A.K.Singh, Sr. Endocrinologist, G.D Hospital, Dr V. Ravi, Member K'taka Covid Task Force, Dr N.K Ganguly, Scientist & Former DG, ICMR and Murali Neelakantan, Principal Lawyer, Amicus.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting